GLP-1 Insurance Coverage: Navigating Approvals, Denials & Appeals

This guide covers insurance coverage for all GLP-1 receptor agonist medications, including how to navigate prior authorization, step therapy requirements, coverage denials, and the appeals process.

Insurance coverage for GLP-1 medications varies dramatically by plan type and indication. Commercial employer-sponsored plans provide the broadest coverage, with the majority covering at least one GLP-1 for diabetes and an increasing number covering weight management indications. Individual marketplace (ACA) plans vary by state and plan level but generally cover diabetes indications. Medicare Part D covers GLP-1 medications for diabetes but has historically excluded anti-obesity medications, though legislative efforts to change this are underway. Medicaid coverage varies by state — most state Medicaid programs cover GLP-1s for diabetes, but fewer cover them for weight management. Tricare covers diabetes-indicated GLP-1s but coverage for obesity indications has been limited. Self-funded employer plans have the most flexibility and are increasingly adding obesity medication coverage.

• Commercial (employer): Most cover for diabetes; ~50-60% now cover for weight management
• ACA Marketplace: Generally cover for diabetes; weight management coverage varies
• Medicare Part D: Covers for diabetes; anti-obesity drugs generally excluded (pending legislation)
• Medicaid: Varies by state; most cover for diabetes; fewer for weight management
• Tricare: Covers for diabetes; limited obesity coverage
• Self-funded employer plans: Most flexibility; increasingly covering obesity medications

Most insurance plans require prior authorization (PA) before covering GLP-1 medications, even for diabetes indications. A PA typically requires documentation of the patient's diagnosis (T2D or qualifying BMI), previous medication trials (step therapy), and relevant lab work. For diabetes indications, common PA criteria include a documented HbA1c above a threshold (often 7.0% or higher), failure of or intolerance to first-line therapy (metformin), and sometimes a second-line agent. For weight management indications, PA criteria typically require a documented BMI of 30 or greater (or 27+ with a comorbidity), evidence of a structured diet/exercise program, and often failure of previous weight-loss attempts. Processing times range from 24 hours to 2 weeks. Electronic prior authorizations (ePAs) through CoverMyMeds or similar platforms are faster.

Step therapy (also called "fail first") policies require patients to try one or more less expensive medications before the insurer will cover a GLP-1. For diabetes, step therapy commonly requires a trial of metformin (typically 3 months) and sometimes a second agent such as a sulfonylurea, SGLT2 inhibitor, or DPP-4 inhibitor. For weight management, insurers may require documentation of a structured diet and exercise program (6-12 months), a trial of older weight-loss medications (such as phentermine/topiramate or naltrexone/bupropion), and sometimes participation in a formal weight management program. Step therapy requirements can be frustrating, but documenting each failed step creates a stronger case for eventual GLP-1 approval. Some state laws limit step therapy requirements, and exceptions can be requested for medical contraindications.

• Metformin is the most common required first step for diabetes
• Some plans require 2-3 failed diabetes medications before approving a GLP-1
• Weight management step therapy may require 6-12 months of documented lifestyle intervention
• Contraindications to step therapy drugs (e.g., metformin intolerance) can expedite approval
• Keep records of all previous medication trials, durations, and reasons for discontinuation

If your GLP-1 prior authorization is denied, you have the right to appeal. The appeals process typically includes three levels: internal appeal to the insurer, external review by an independent third party, and in some cases, a state insurance commissioner complaint. For the initial appeal, gather supporting documentation including your prescriber's letter of medical necessity, relevant clinical trial data (cite the SELECT trial for cardiovascular benefit in obese patients), your complete medication history showing step therapy completion, lab results, BMI documentation, and any weight-related comorbidities. The appeal letter should explain why the specific GLP-1 medication is medically necessary and why alternatives are inadequate. Approximately 40-60% of initial GLP-1 coverage appeals succeed. External reviews, conducted by physicians not employed by the insurer, have even higher overturn rates. Your prescriber's office often has staff experienced in writing appeal letters.

• File the appeal within the deadline (typically 30-180 days from denial)
• Include a detailed letter of medical necessity from your prescriber
• Cite clinical trial evidence, especially SELECT cardiovascular outcomes data
• Document all previous weight-loss attempts and medication trials
• Request a peer-to-peer review (your doctor speaks directly with the insurer's physician)
• If internal appeal fails, file for external independent review

Medicare Part D has been the largest coverage gap for GLP-1 weight management medications. The Social Security Act has historically prohibited Medicare from covering drugs used for weight loss or cosmetic purposes. The Treat and Reduce Obesity Act (TROA) has been repeatedly introduced in Congress to remove this exclusion, and the political momentum has grown following the SELECT trial cardiovascular data. If enacted, TROA would allow Medicare to cover FDA-approved anti-obesity medications, significantly expanding access for the 65+ population where obesity-related cardiovascular risk is highest. In the meantime, Medicare beneficiaries with type 2 diabetes can access diabetes-indicated GLP-1s (Ozempic, Mounjaro) through Part D. Medicaid coverage varies by state — as of 2026, a growing number of state Medicaid programs have added anti-obesity medication coverage, driven by evidence that treating obesity reduces expensive downstream complications like heart disease, diabetes, and joint replacements.